The MRI-safe neurostimulation systems market is expected to reach USD 319.5 Million by 2025 and is expected to steadily grow at a CAGR of 7.1% to reach USD 634.3 Million by 2035. In 2024, MRI-safe neurostimulation systems market have generated roughly USD 298.3 Million in revenues.
MRI-safe neurostimulation devices are implantable medical devices that provide therapeutic electrical stimulation to the target neural structures without impeding the use with MRI scans. MRI-safe devices are equipped with state-of-the-art materials and circuit designs to minimize magnetic field interaction risks and allow patients to fearlessly go for MRIs without worry of removal or device failure.
Increasing incidence of chronic pain with age, the diminishing of other disease conditions like Parkinsons, epilepsy, and movement disorders have made the necessity of neurostimulation therapy. Introduction of MRIs as commonplace tests, a rising need for MRI-compatible devices significantly attributes to the growth of the market. Finally, with miniaturization, rechargeable batteries, and the ability of focal stimulation to enhance patient outcomes and quality of life, further anticipate the market growth.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 319.5 Million |
| Industry Value (2035F) | USD 634.3 Million |
| CAGR (2025 to 2035) | 7.1% |
Historical trends impacted from 2020 up to 2024 with the increase of the acceptance of MRI-safe neurostimulation systems. Increase in diagnosis and treatment of neurological diseases, like chronic pain, Parkinson's disease, and epilepsy, which they transitioned to from the first disruption by COVID-19 outbreak. During this period, non-invasive and long-term therapies emerged.
Moreover, the rising demand for MRI scans with improved imaging capabilities encouraged patients to start looking for substitutes that are MRI-compatible. Additionally, support extended by by agencies such as the FDA and EMA for facilitating the introduction of new systems in the market anticipate the growth of the market.
Continued investments were made during the period in research and development to facilitate further education on safety, wireless communication, and recharge designs for the device. Alliances built in the industry and clinical studies demonstrating safety and efficacy further provided for confidence-building acceptance and the common purpose within clinical practice. These are few of the factors anticipating the growth of the market during forecast period.
Explore FMI!
Book a free demo
The burgeoning use of MRI-safe neurostimulation systems in North America is being buttressed by some fundamental trends. The widespread chronic pain, Parkinson's disease, and epilepsy, have continued to put pressure on sophisticated neurostimulation treatments. The availability of MRI for imaging, and other modalities depend on MRI for diagnostics, MRI compatibility for implants is now a key consideration. Regulatory support (especially from the USA FDA) has accelerated the approval of MRI-conditional devices and strengthened clinician confidence.
Moreover, miniaturization of the devices and the enhancement of battery life with wireless programming technology have made for even greater acceptability and comfort by patients. The reimbursement coverage from private payers and plans sponsored by the government, such as Medicare, is also improving access, with North America positioned as the foremost region for acceptance.
In Europe, the increased purchase of MRI-compatible neurostimulation systems is primarily due to converging demographic, technological, and healthcare reasons. Moreover, the growing demand for prolonged neuromodulation treatments is due to demographic changes toward aging populations and increasing incidences of neurological disorders, such as Parkinsons; chronic pain; or, epilepsy. The highly developed healthcare structure of Europe and the high use of MRI diagnostics demand safe-to-image implants.
These also have facilitated a faster market introduction for MRI conditional products through regulatory support and CE-mark approvals. Sophisticated neurostimulation solutions are, therefore, accessible to patients through public healthcare systems in Germany, France, and the UK. Growing awareness and partnerships between device companies and European research centers continue to fuel innovation and clinical adoption throughout the region.
Sales of MRI-safe neurostimulation systems in the Asia Pacific region stand poised for potential further growth spurred by increasing awareness of health care, an increasingly constructing medical infrastructure, and family burden owing to growing numbers of neurological disorder patients ranging from epilepsy and chronic pain to Parkinson's disorder. Sophistication of diagnostics such as MRI in China, Japan, and India translates into increased demand for these implants.
The demand is underpinned by government expenditure on modernization of healthcare and better access to neuromodulation treatments. Higher adoption of services supported by technology is also an increased disposable income and continued urbanization. US-based medical device manufacturers are also sharpening their presence in Asia by local partnership and distribution channels in order to sell low-cost MRI-safe devices to push up sales in developed and emerging APAC countries.
High cost and Device Complexity Hinders the Adoption of MRI-Safe Neurostimulation Systems
The cost and complexity of development and implantation of devices are high. This aspect forms one of the critical challenges of the MRI-safe neurostimulation systems market. Such devices require robust engineering to function safely in an environment with a strong magnetic field; for this, special materials and high-level circuitry have to be included, increasing production costs significantly.
Regulatory approval of MRI-conditional labeling is highly demanding and requires extensive clinical trials which also increase the development time and expenditure. As a result, these devices are not accessible to MRI-compatible neurostimulation systems, especially in areas outside major cities, representing yet another barrier to wider adoption even as demand increases for safer neuromodulation treatments that are compatible with contemporary imaging practices.
Expansion of Minimally Invasive Neuromodulation Therapies in Developing Markets
Demand for compatible neurostimulation devices will increase enormously in Asia-Pacific, Latin America, and the Middle East, where this modality is beginning to see much diagnostic application in MRI. They can offer innovative marketers many opportunities to provide these markets with cost-effective solutions while being MRI-conditional. Another issue is the increase in the elderly population and the growing prevalence of chronic neurological disorders, which keeps alive, always, a market demand.
By establishing local production facilities, develop physician education programs, and build strategic relationships with local hospitals, companies are first movers. Besides, wireless technology innovation and battery-free implants will enhance safety and convenience for MRI-safe systems, opening up new possibilities for pain management and treatment of functional neurological disorders worldwide.
Integration of Conditional MRI Labeling Enhances Clinical Adoption anticipates the Growth of the Market
The conditional MRI labeling integration within neurostimulation systems is enhancing significantly clinical workflow and patient care. This way, systems were designed to operate safely under specific MRI conditions-i.e., magnetic field strength, scan time, and device placement-thereby allowing patients with an implant to undergo necessary MRI diagnostics without device removal.
Considering that MRI is still paramount to the follow-up of neurological and musculoskeletal diseases, MRI conditional systems eliminate the risks of device migration, heating, or image distortion. Increasingly more devices are being manufactured to ASTM and ISO standards concerning the operational necessities set forth by the radiology department.
Rise in FDA and CE Approvals Fuels Competitive Innovation demonstrates the Growth of the Market
Competitively innovative waves are being created among the major players of MedTech due to the increase in FDA and CE approvals for MRI-safe neurostimulation systems. Regulatory approval provides safety assurance of a given system under MRI conditions, which carries weight in the market for its manufacturers.
Thus, companies like Medtronic, Boston Scientific, and Abbott raised their research and development budgets for technological advancement for devices responsive to changing MRI safety standards without compromising therapeutic efficacy. Therefore, these approvals are not only milestones but also strategic opportunities that facilitate much wider penetration within hospitals and outpatient contact.
Shift Toward Closed-Loop MRI-Safe Systems is an Ongoing Trend in the Market
MRI-compatible neurostimulation systems with real-time feedback to maximize therapy. They will have sensors monitoring some neural or physiological activity and adjust stimulation parameters in real time to enhance individuation and efficacy of the therapy. Making these systems MRI-compatible adds an additional level of difficulty since the real-time sensing cannot interfere with the MRI signal. shielded cables and low-noise electronics are used by manufacturers in their devices to allow compatibility without compromising device performance.
This thus creates reconciliation between closed-loop functionality and safety from MRI effects; thus, patients can now be run through their imaging safely, while their neurostimulation therapy can also be tuned almost in real-time should continuous disorders like chronic pain, epilepsy, or Parkinson's disease occur and the patient is transformed by patient-focused neuromodulation.
Advanced Materials and Coatings for MRI Compatibility
Another emerging trend within the MRI-safe neurostimulation market is the incorporation of sophisticated materials and biocompatible coatings as passive approaches at minimizing magnetic susceptibility and heating effects during MRI procedures. In fact, metals conventionally used in implantable devices may cause deflections in MRI images or produce heating once subjected to strong magnetic fields, becoming safety hazards.
Thus, producers introduce into their products non-ferromagnetic alloys, ceramic insulators, and polymer-based encapsulation for structural robustness while minimizing MRI interference. These innovations not only increase safety but also enhance design flexibility for miniaturization of devices and multichannel stimulation. This materials-driven movement is critical for enabling long-term implantation and greater MRI accessibility for chronic neurological care settings by improving MRI compatibility in leads, electrodes, and IPG casings.
The MRI-safe neurostimulation systems market was gradually growing in acceptance between 2020 and 2024 owing to increasing demand for treatment of chronic pain and neurological disorders along with rising volumes of MRI scans. Furthermore, regulatory clearances, device shielding improvements, materials, and conditional labeling have also helped build acceptance. Between 2025 and 2035, the market will be a function of growing geriatric populations; a growing preference for use of non-invasive neuromodulation would accord level of importance to differing access to MRIs.
Shifts in the MRI-Safe Neurostimulation Systems Market from 2020 to 2024 and Future Trends 2025 to 2035
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Increased FDA and CE approvals of MRI-conditional devices; enhanced labeling requirements; post-pandemic surge towards imaging access among implant patients |
| Technological Advancements | Launch of MRI-conditional IPGs and leads, improved shielding, and artifact reduction technologies. |
| Consumer Demand | Growing demand based on increase in chronic pain, epilepsy, and movement disorders; expanding demand for safe imaging alternatives for implanted patients. |
| Market Growth Drivers | Increased rate of diagnoses, higher volumes of MRI scans, and wider MRI-safe device awareness. |
| Sustainability | Early emphasis on minimizing device recalls and maximizing reusability of external components. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Harmonized global MRI safety standards, accelerated approval times for implantable systems, and increased insurance coverage for MRI-compatible neuromodulation. |
| Technological Advancements | Convergence of AI-based closed-loop systems, energy-efficient IPGs, and new materials such as carbon-based conductors and polymer casings to enhance MRI compatibility. |
| Consumer Demand | Sustained demand for individualized neuromodulation therapies, non-invasive or minimally invasive implants, and continuous MRI diagnostics in long-term care management. |
| Market Growth Drivers | Increased application in developing markets, increased remote monitoring solutions, and increased cooperation between imaging centers and neuromodulation clinics. |
| Sustainability | Improvement in recyclable implants, low-energy systems, and environmentally friendly manufacturing techniques for long-term implantable devices. |
Market Outlook
The United States would be driving up adoption early with the FDA clearances followed to have on very high MRI scan volumes coupled with a large user base of neurostimulators. Rising chronic pain and diagnosis of many cases of Parkinson's, together with integration of AI-based diagnostics, provide a healthy environment. Strategic interaction between medtech companies and health networks facilitates device penetration across hospitals, outpatient facilities, and veterans' health networks.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 3.2% |
Market Outlook
Germany's market is majorly driven by stringent regulatory compliance, advanced imaging infrastructure, and high prevalence of neurodegenerative disorders. The focus is on providing access for public hospitals to MRIs and the rising demand for geriatric care that can be provided in an MRI-safe manner. Government initiatives for reimbursement policies and precision medicine programs also contribute significantly to growth, supported by in-house innovation in biocompatible materials.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 3.8% |
Market Outlook
Increasing numbers of cases being diagnosed with neurological conditions rising accessibility to health services and enhancement of availability of MRI in urban areas are some of the reasons behind India's growth in the market. Budget allocation by government about neurology departments with increasing flow of medical tourism is driving demand. There is increased awareness on MRI-safe implants among doctors, which is further creating opportunities for global manufacturers entering India through localization, tie-ups, and low-cost products.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 5.6% |
Market Outlook
China's market is growing rapidly on the foot of the new, speedy uptake of hospital MRIs and also due to the burdens associated with increasing numbers of epilepsy and stroke. The reform of the healthcare sector by the government and alignment with digital health development tips in favor of MRI-safe neurostimulators. Local technology companies develop affordable, MRI-friendly systems whereas foreign competitors bask in the glory of partnerships, awareness campaigns, and collaboration in regulation.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 6.2% |
Market Outlook
Japan is blessed with an extraordinarily aged population, having high MRI use and demand in accurate neuromodulation. Focused on minimal invasion to technologies and strict device safety standards drive uptake in the nation. Strong R&D on closed-loop technologies with MRI-safe materials, supported by efficient regulation, would promote market sustainability and advance it in the long run.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.8% |
The implantable segment dominates the market due to its use in managing long-term neurological conditions
Parkinson's disease, epilepsy, chronic pain, and depression, this market share is the largest application of implantable leads in MRI-safe neurostimulation systems. These diseases require continuous therapy, and repetitive MRI scans are done for monitoring purposes. The MRI-safe implantable devices have the advantage of continuing therapy while ensuring patient safety for imaging.
Advances in lead insulation and battery life and better shielding have contributed to the increased compatibility of devices with MRI. Faster processing of approvals by regulatory agencies and the increased popularity among doctors as largely reliable and effective devices for long-term therapy have made them the standard of therapy in neuromodulation.
The transcutaneous segment holds a substantial share due to its non-invasive nature
The feature make transcutaneous share much in terms of large share because this shares completely non-invasive, easy to implement, and gaining popularity in acute pain relief, rehabilitation, and short-term neurological conditions. They are of great use to patients who may be poorly qualified for surgery and work in an outpatient setting.
Increased awareness of neuromodulation and thus a greater demand for low-cost, low-risk therapy has led to fast acceptance of the transcutaneous devices to be used for short-term situations. Also, innovations in the design of the electrodes and advances in wearable form factors have really proliferated applications. They are not substitutes for implantable devices; they offer a helpful, MRI-safe alternative in certain clinical and homecare settings.
Hospitals & Clinics segment dominates the market due to its comprehensive infrastructure
Hospitals lead the market for MRI-safe neurostimulation systems largely because they can perform sophisticated, high-risk operations and deliver extensive post-surgical care. Soft tissue repair surgeries-herniation repair, ligament reconstruction, or wound closure-are sometimes in need of a sophisticated surgical infrastructure, a multidisciplinary team, and critical care, all of which are found in hospitals.
Hospitals can also take better advantage of such advanced technologies as robotic-assisted surgery and biologic implants. Reimbursement schemes would favor hospital-based surgeries, especially for the inpatient procedures. The large number of trauma cases, emergency surgeries, and orthopedic specialist interventions also solidifies the leading position of the hospital segment in this market.
Ambulatory Surgical Centers (ASCs) hold a substantial market share due to their growing role in minimally invasive neuromodulation procedures
ASCs, having a substantial market share while continuing to provide minimally invasive neuromodulation on an outpatient basis, have been accommodating the patients. Low procedural costs, short hospital stay, and speedy recovery make ASCs favorable to payers as well as patients.
With MRI-compatible neurostimulation systems providing more and more options for same-day implantation and effective follow-ups, ASCs have reportedly become popular for their efficacy in operation. Most ASCs are affiliated with local imaging centers, or in the process of adding MRI capability, which would positively ensure the safe application of MRI-compatible devices following implantation. Therefore, ASCs are well-positioned for further market expansion.
Competition in MRI-safe neurostimulation systems, there have been advances in miniaturization. These include MRI-conditional materials and closed-loop feedback technology and systems in devices. Current leaders in the market are seizing technological advances in neuromodulation algorithms or power optimization for product differentiation. The FDA and EMA now speed setting up for companies to meet the MRI conditional labeling requirements, thus pushing companies quickly to continuing replacing older systems with newer ones.
The medtech majors are forming strategic alliances, mergers and acquisitions, and licensing agreements as they look into expanding MRI-safe offerings, together with some startups focused on neurology. As demand for safety requirements related to long-term imaging compatibility is increasing, especially in the case of MRI systems, firms are competing with one another while extending their boundaries to most parts of the globe and application fields.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic Inc. | 33.6% to 38.5% |
| Boston Scientific | 20.4% to 22.6% |
| Biotronik | 15.1% to 17.2% |
| Cyberonics, Inc. | 4.6% to 6.8% |
| Other Companies (combined) | 12.1% to 15.4% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic Inc. | Medtronic is a world leader in MRI-compatible neurostimulation systems with a robust pipeline of deep brain, spinal cord, and sacral neuromodulators |
| Boston Scientific | Boston Scientific has been selectively developing MRI-safe neurostimulation systems utilizing the Wave Writer Alpha™ and Spectra™ SCS systems, which assure compatibility for whole-body MRIs. |
| Biotronik | Biotronik is enhancing the MRI-conditionality of cardiac and neurostimulation systems. It espouses bio- adaptivity and lead designs that withstand high MRI field strengths while preserving signal integrity. Its neurostimulation systems are comfortable for the patient and designed for maximum accessibility to MRI |
| Cyberonics, Inc. | Cyberonics, under LivaNova, provides MRI-compatible vagus nerve stimulation (VNS) systems for epilepsy and depression treatment. The company has upgraded its VNS Therapy® systems to allow full-body MRI access through advanced filtering and safety measures. |
Key Company Insights
Medtronic Inc.
Medtronic is the leader in the area of MRI-safe neurostimulation systems, known for its wide range of implantable neuromodulation devices used in pain therapy, movement disorders, and dysfunctions of urination. It provides to the industry not just a cutting-edge innovation but full-body MRI-conditional systems such as Intellis™ and Percept™ PC with BrainSense™ technology.
Boston Scientific
Boston Scientific becomes the leading worldwide company on neurostimulation therapy with the position of entry in MRI-safe devices through its WaveWriter Alpha™ sprocket for it primarily emphasizes on individualizing pain therapy through dual waveform delivery along with position-adaptative stimulation.
Biotronik
Biotronik is among the famous contenders in the MRI-safe neurostimulation systems in Europe and is well known for engineering precision and biocompatible device designs. The company, inheriting cardiac implants, conditioned its neurostimulation business by putting emphasis on lead longevity, patient safety in under 1.5T and 3T MRI scans, and longevity of the devices.
The overall market size for MRI-safe neurostimulation systems market was USD 319.5 Million in 2025.
The MRI-safe neurostimulation systems market is expected to reach USD 634.3 Million in 2035.
Rising prevalence of neurological disorders and increased need for imaging compatibility anticipates the growth of the MRI-safe neurostimulation systems market.
The top key players that drives the development of MRI-safe neurostimulation systems market are Medtronic Inc., Boston Scientific, Biotronik, Cyberonics, Inc. and Nevro Corporation.
Implantable segment by product is expected to dominate the market during the forecast period.
MRI-Safe Neurostimulation Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
